BCMA GPRC5D T cells / Eureka Therap - LARVOL DELTA

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma (Businesswire) - "Eureka Therapeutics, Inc. announced today that Eureka and Memorial Sloan Kettering Cancer Center (MSK) entered into a license agreement with Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D). The GPRC5D binding domain was discovered using Eureka’s proprietary E-ALPHA® antibody discovery platform and developed under a collaboration agreement between Eureka and MSK....Under the terms of the agreement, Sanofi has exclusive rights to the GPRC5D binder for non-CAR use."

Licensing / partnership • Hematological Malignancies • Multiple Myeloma • Oncology

COMy 2020 | The benefits of bispecific antibodies for treating multiple myeloma (VJHemOnc) - "Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the emergence of bispecific antibodies to treat multiple myeloma. Bispecific antibodies work in a similar way to CAR T-cells to destroy tumors, however, they do not have the same constraints as CAR T-cells....This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress."

Interview • Video